Waters Corporation and BD Complete Transformative BDS Business Merger: Key Financial Details and Shareholder Implications

Overview of the Transaction

Waters Corporation (“Waters”) and Becton, Dickinson and Company (“BD”) have executed a significant strategic transaction that combines BD’s Biosciences and Diagnostic Solutions businesses (the “BDS Business”) with Waters through a Reverse Morris Trust structure. This transaction, finalized on February 9, 2026, involved a spin-off and subsequent merger, creating a wholly owned subsidiary under Waters. The newly combined BDS Business brings together advanced capabilities in instruments, informatics, reagents, single-cell multiomics, and a comprehensive suite of microbiology and infectious disease diagnostic solutions.

Key Financial Highlights: Q1 FY2026 vs. Q1 FY2025

• Revenues: The BDS Business reported total net sales of \$766 million for the quarter ended December 31, 2025, compared to \$834 million for the same period in 2024—a decline of 8.2%. Product sales fell from \$727 million to \$652 million, while service sales increased modestly from \$107 million to \$114 million.
• Operating Income: Operating income dropped sharply from \$94 million in Q1 FY2025 to \$35 million in Q1 FY2026, reflecting increased operating costs and a decline in revenues.
• Net Income: Net income stood at \$49 million for Q1 FY2026, a decrease from \$78 million in the prior year period. This was despite a favorable income tax benefit of \$16 million in Q1 FY2026, compared to a \$15 million tax provision in Q1 FY2025.
• Comprehensive Income: Despite the lower net income, comprehensive income for the quarter was \$50 million, compared to \$33 million in the prior year, mainly due to a positive foreign currency translation adjustment of \$1 million in Q1 FY2026 versus a negative \$45 million in the prior year.

Segment Performance

• Biosciences: Revenue fell to \$327 million from \$361 million year-on-year. Segment operating income was \$94 million (28.7% of revenues), down from \$139 million (38.5%).
• Diagnostic Solutions: Revenue dropped to \$439 million from \$473 million, with segment operating income at \$69 million (15.7% of revenues), down from \$102 million (21.6%).
• The revenue decrease was primarily driven by lower product sales across both segments, while service sales saw a moderate increase.

Balance Sheet and Cash Flow

• Total Assets: As of December 31, 2025, total assets were \$3.94 billion, down from \$4.03 billion on September 30, 2025.
• Cash Position: Cash and equivalents decreased to \$67 million from \$74 million at the start of the quarter.
• Trade Receivables: Significant reduction to \$521 million from \$597 million, indicating improved collections or lower sales activity.
• Inventories: Rose slightly to \$775 million from \$743 million.
• Net Cash from Operating Activities: \$132 million in Q1 FY2026, down from \$162 million in Q1 FY2025.
• Net Cash Used for Investing Activities: \$29 million outflow, consistent with the prior year.
• Net Cash Used for Financing Activities: \$110 million outflow, reflecting continued cash transfers to the parent company prior to the merger close.

Important Shareholder Information and Potential Price-Sensitive Items

• Completion of Spin-Off and Merger: The spin-off and merger with Waters, including a \$4 billion cash distribution to BD, fundamentally changes the structure and ownership of the BDS Business. Shareholders should consider the impact of this new structure, including the integration and synergy risks and opportunities.
• Restructuring and Integration Costs: The quarter included \$4 million in integration, restructuring, and transaction expenses, up from \$2 million in the prior year, indicating ongoing costs related to the transaction.
• Legal and Regulatory Matters: The BDS Business is involved in ongoing legal and regulatory matters, including a settlement with the Italian government over medical device payback legislation. The company paid to settle historical obligations but notes uncertainty regarding potential future liabilities for subsequent years.
• Asset Impairment: In Q1 FY2025, the BDS Business recorded a significant non-cash asset impairment charge of \$30 million in the Diagnostic Solutions segment. While no new impairments were recorded in Q1 FY2026, this highlights the risk of further write-downs.
• Accounting Changes: Upcoming accounting standards may require more detailed future disclosures regarding expense types and income tax reconciliation, which could affect reported results and transparency.
• Tax Rate Volatility: The company reported an unusually favorable effective tax rate of (49.1)% in Q1 FY2026, driven by discrete items. Such volatility may not be sustainable and could impact future after-tax earnings.
• Segment Allocation and Cost Structure Risks: Historical financials include significant allocations from BD corporate functions. After the transaction, the BDS Business will need to manage these functions independently or through transitional service agreements, which may impact future cost structures and profitability.
• No Major Customer Concentration: No individual customer accounted for more than 10% of revenues, which reduces concentration risk but also means performance is broadly tied to general market trends.

Other Notable Details

• Supplier Finance Programs: The BDS Business participates in supplier finance programs, with \$28 million in payables outstanding as of December 31, 2025. These arrangements do not require pledging of assets or guarantees.
• Goodwill and Intangible Assets: Goodwill increased slightly due to currency translation, now totaling \$897 million. Amortization expense for intangible assets was \$10 million in the quarter.
• Contract Liabilities and Performance Obligations: As of December 31, 2025, the BDS Business had \$127 million in contract liabilities, with an estimated \$257 million in remaining performance obligations for service contracts and \$472 million for reagent/consumable minimum purchase commitments.

Potential Impact on Share Price

The combination of BD’s BDS Business with Waters is a transformative deal that could deliver significant synergies and market advantages, but also brings execution and integration risks. The decline in revenues and operating income, ongoing restructuring costs, and exposure to legal liabilities and regulatory changes are all critical factors for shareholders. Additionally, the unusual income tax benefit in the recent quarter boosted net income, but such effects may not recur.

Investors should closely monitor the progress of post-merger integration, the realization of expected synergies, and any future developments in legal or regulatory exposures, as these could materially affect valuation and share performance.

Disclaimer

This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult with financial advisors before making investment decisions. The information herein is based on the latest available unaudited financial statements and may be subject to change.

View WATERS CORP /DE/ Historical chart here